Immunofluorescent analysis of HER-2 (green) showing staining in the membrane of SK-BR-3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a HER-2 monoclonal antibody (Product # MA5-12998) in 3% BSA-PBS at a dilution of 1:100 and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a flourescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.
|Tested species reactivity||Human|
|Published species reactivity||Hamster, Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Intact SKBR-3 breast cancer cells|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||Assay Dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:200|
|Immunomicroscopy (IM)||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunoprecipitation (IP)||See 2 publications below|
|Flow Cytometry (Flow)||See 1 publications below|
|Immunocytochemistry (ICC)||See 4 publications below|
|Immunohistochemistry (IHC)||See 1 publications below|
|Western Blot (WB)||See 1 publications below|
|Gel Shift (GS)||See 1 publications below|
|ELISA (ELISA)||See 1 publications below|
MA5-12998 targets HER-2 in ICC/IF, IHC (F), IHC (P) and IM applications and shows reactivity with Human samples.
The MA5-12998 immunogen is intact SKBR-3 breast cancer cells.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
IP-MS enrichment of ERBB2 (LFQ intensity): ERBB2 was enriched 85-fold from HCT116 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and ERBB2 antibody (Part No. MA5-12998). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
MA5-12998 was used in immunoprecipitation to investigate the state of HER1-HER2 interaction and modification in cell lines and tumors
|DeFazio-Eli L,Strommen K,Dao-Pick T,Parry G,Goodman L,Winslow J||Breast cancer research : BCR (13:null)||2011|
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
MA5-12998 was used in immunoprecipitation to investigate the effect of lapatinib on cell proliferation regulated by EGFR/HER2
|Gilmer TM,Cable L,Alligood K,Rusnak D,Spehar G,Gallagher KT,Woldu E,Carter HL,Truesdale AT,Shewchuk L,Wood ER||Cancer research (68:571)||2008|
Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.
MA5-12998 was used in flow cytometry to validate a method for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens
|Larson JS,Goodman LJ,Tan Y,Defazio-Eli L,Paquet AC,Cook JW,Rivera A,Frankson K,Bose J,Chen L,Cheung J,Shi Y,Irwin S,Kiss LD,Huang W,Utter S,Sherwood T,Bates M,Weidler J,Parry G,Winslow J,Petropoulos CJ,Whitcomb JM||Pathology research international (2010:null)||2010|
Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy.
MA5-12998 was used in immunocytochemistry to study silica-gold nanoshells as potential probes for HER2-overexpression in ex vivo breast tissue
|Bickford LR,Agollah G,Drezek R,Yu TK||Breast cancer research and treatment (120:547)||2010|
Enhanced multi-spectral imaging of live breast cancer cells using immunotargeted gold nanoshells and two-photon excitation microscopy.
MA5-12998 was used in immunocytochemistry to develop a method for multi-spectral imaging of live breast cancer cells using immunotargeted gold nanoshells
|Bickford L,Sun J,Fu K,Lewinski N,Nammalvar V,Chang J,Drezek R||Nanotechnology (19:null)||2008|
Immunonanoshells for targeted photothermal ablation of tumor cells.
MA5-12998 was used in immunocytochemistry to study the use of immunonanoshells for targeted photothermal ablation of tumor cells
|Lowery AR,Gobin AM,Day ES,Halas NJ,West JL||International journal of nanomedicine (1:149)||2007|
Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.
MA5-12998 was used in immunocytochemistry to examine the mechanism for the lapatinib sensitivity in breast cancer cell lines
|Hegde PS,Rusnak D,Bertiaux M,Alligood K,Strum J,Gagnon R,Gilmer TM||Molecular cancer therapeutics (6:1629)||2007|
Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients.
MA5-12998 was used in immunohistochemistry to study the predictive value of tumor cell expression of HLA-DM in breast carcinoma patients
|Oldford SA,Robb JD,Codner D,Gadag V,Watson PH,Drover S||International immunology (18:1591)||2006|
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
MA5-12998 was used in western blot to develop and characterize specific antibodies targeting EGFR family
|Horak E,Heitner T,Robinson MK,Simmons HH,Garrison J,Russeva M,Furmanova P,Lou J,Zhou Y,Yuan QA,Weiner LM,Adams GP,Marks JD||Cancer biotherapy and radiopharmaceuticals (20:603)||2005|
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.
MA5-12998 was used in EMSA to investigate the influence of ErbB-2 on COX-2 expression and its mechanism
|Wang SC,Lien HC,Xia W,Chen IF,Lo HW,Wang Z,Ali-Seyed M,Lee DF,Bartholomeusz G,Ou-Yang F,Giri DK,Hung MC||Cancer cell (6:251)||2004|
C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment.
MA5-12998 was used in ELISA to investigate the prognostic value of C-erbB2 oncoprotein in Herceptin treatment
|Wu JT||Clinica chimica acta; international journal of clinical chemistry (322:11)||2002|